MeSH D003233 - allergic conjunctivitis
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| A.H. Robins Company | Prednisone | Prednisone |  | 1982-01-01 |  |  |
| AbbVie | Ketorolac tromethamine | Acular |  | 1992-11-09 |  |  |
| Ketorolac tromethamine | Acuvail | 2024-08-05 | 2009-07-22 |  |  | |
| Alcaftadine | Lastacaft | 2027-03-19 | 2010-07-28 |  |  | |
| Alcon Research | Loteprednol etabonate | Eysuvis | 2033-05-03 | 2020-10-26 |  |  |
| Loteprednol etabonate | Inveltys | 2033-05-03 | 2018-08-22 |  |  | |
| Olopatadine | Pataday |  | 1996-12-18 |  |  | |
| Ketotifen | Zaditor |  | 2008-09-02 |  |  | |
| Alembic Pharmaceuticals | Azelastine | Azelastine |  | 2019-03-20 |  |  |
| Ketorolac tromethamine | Ketorolac Tromethamine |  | 2022-11-02 |  |  | |
| Olopatadine | Olopatadine |  | 2019-04-29 |  |  | |
| Bepotastine | Bepotastine |  | 2023-04-05 |  |  | |
| Alcaftadine | Alcaftadine |  | 2024-10-02 |  |  | |
| Alkem Laboratories | Azelastine | Azelastine |  | 2017-08-18 |  |  |
| Allergan | Ketorolac tromethamine | Acular |  | 1997-11-03 |  |  |
| Epinastine | Elestat |  | 2003-10-16 |  |  | |
| Phenylephrine, Pyrilamine | Prefrin-a |  | 1982-01-01 |  |  | |
| Ketorolac tromethamine | Ketorolac Tromethamine |  | 1997-09-19 |  |  | |
| Prednisone | Prednisone |  | 1982-01-01 |  |  | |
| Pyrilamine | Pyrilamine |  | 1982-01-01 |  |  | |
| Pseudoephedrine, TRIPROLIDINE | Triprolidine Pseudoephedrine |  | 1984-01-13 |  |  |
1
2
3
4
5
6
...
13
>
Clinical Trials
Historical Success Rate
Phase 1
67%4/6
Phase 2
49%19/39
Phase 3
83%35/42
Approved: 21Overall Success rate: 27%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
4
5
6
...
9
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use